{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:09:11Z","timestamp":1792710551358,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2008,8,28]],"date-time":"2008-08-28T00:00:00Z","timestamp":1219881600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1007\/s00198-008-0712-1","type":"journal-article","created":{"date-parts":[[2008,8,27]],"date-time":"2008-08-27T06:05:19Z","timestamp":1219817119000},"page":"1395-1408","source":"Crossref","is-referenced-by-count":478,"title":["Case finding for the management of osteoporosis with FRAX\u00ae\u2014assessment and intervention thresholds for the UK"],"prefix":"10.1007","volume":"19","author":[{"given":"J. A.","family":"Kanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. V.","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Strom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Borgstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Oden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"National Osteoporosis Guideline Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,8,28]]},"reference":[{"key":"712_CR1","volume-title":"Osteoporosis: clinical guidelines for the prevention and treatment 1999","author":"Royal College of Physicians","year":"1999","unstructured":"Royal College of Physicians (1999) Osteoporosis: clinical guidelines for the prevention and treatment 1999. Royal College of Physicians, London"},{"key":"712_CR2","volume-title":"Update on pharmacological interventions and an algorithm for management 2000","author":"Royal College of Physicians and Bone and Tooth Society of Great Britain","year":"2000","unstructured":"Royal College of Physicians and Bone and Tooth Society of Great Britain (2000) Update on pharmacological interventions and an algorithm for management 2000. Royal College of Physicians, London"},{"key":"712_CR3","volume-title":"Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians","author":"Royal College of Physicians","year":"2002","unstructured":"Royal College of Physicians (2002) Glucocorticoid-induced osteoporosis. Guidelines on prevention and treatment. Bone and Tooth Society of Great Britain, National Osteoporosis Society and Royal College of Physicians. Royal College of Physicians, London"},{"key":"712_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","volume":"7","author":"JA Kanis","year":"1997","unstructured":"Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D, European Foundation for Osteoporosis and Bone Disease (1997) Guidelines for diagnosis and management of osteoporosis, Osteoporos Int 7:390\u2013406","journal-title":"Osteoporos Int"},{"key":"712_CR5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00198-008-0560-z","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399\u2013428","journal-title":"Osteoporos Int"},{"key":"712_CR6","volume-title":"Report on osteoporosis in the European Community","author":"European Community","year":"1998","unstructured":"European Community (1998) Report on osteoporosis in the European Community. EC, Strasbourg"},{"key":"712_CR7","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis JA (2002) Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359:1929\u20131936","journal-title":"Lancet"},{"key":"712_CR8","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00198-004-1689-z","volume":"16","author":"C Laet De","year":"2005","unstructured":"De Laet C, Oden A, Johansson H, Johnell O, Jonsson B, Kanis JA (2005) The impact of the use of multiple risk indicators for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16:313\u2013318","journal-title":"Osteoporos Int"},{"key":"712_CR9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B et al (2005) Assessment of fracture risk. Osteoporos Int 16:581\u2013589","journal-title":"Osteoporos Int"},{"key":"712_CR10","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00198-007-0343-y","volume":"18","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Oden A, Johnell O, Johansson H, De Laet C, Brown J et al (2007) The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18:1033\u20131046","journal-title":"Osteoporos Int"},{"key":"712_CR11","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00198-007-0543-5","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, McCloskey EV (2008) FRAX\u00ae and the assessment of fracture probability in men and women from the UK. Osteoporos Int 19:385\u2013397","journal-title":"Osteoporos Int"},{"key":"712_CR12","unstructured":"Committee for Medicinal Products for Human Use (CHMP) (2006) Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP\/EWP\/552\/95Rev.2. London, CHMP. Nov 2006"},{"key":"712_CR13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.bone.2004.08.018","volume":"36","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B (2005) Intervention thresholds for osteoporosis in the UK. Bone 36:22\u201332","journal-title":"Bone"},{"key":"712_CR14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1007\/s00198-005-1863-y","volume":"16","author":"C Laet De","year":"2005","unstructured":"De Laet C, Kanis JA, Oden A, Johanson H, Johnell O, Delmas P et al (2005) Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16:1330\u20131338","journal-title":"Osteoporos Int"},{"key":"712_CR15","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2004.03.024","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P et al (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375\u201382","journal-title":"Bone"},{"key":"712_CR16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.bone.2004.06.017","volume":"35","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Eisman J et al (2004) A family history of fracture and fracture risk. Bone 35:1029\u20131037","journal-title":"Bone"},{"key":"712_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1359\/JBMR.040134","volume":"19","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johansson H, Oden A, Johnell O, De Laet C, Melton LJ III et al (2004) A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19:893\u2013899","journal-title":"J Bone Miner Res"},{"key":"712_CR18","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s00198-004-1686-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Oden A, Johansson H, De Laet C, Eisman JA et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16:222\u2013228","journal-title":"Osteoporos Int"},{"key":"712_CR19","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00198-004-1734-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johansson H, Johnell O, Oden A, De Laet C, Eisman J et al (2005) Alcohol intake as a risk factor for fracture. Osteoporos Int 16:737\u201342","journal-title":"Osteoporos Int"},{"key":"712_CR20","unstructured":"Kanis JA, on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK"},{"key":"712_CR21","volume-title":"Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group","author":"World Health Organization","year":"2007","unstructured":"World Health Organization (2007) Assessment of osteoporosis at the primary health care level. Summary Report of a WHO Scientific Group. WHO, Geneva www.who.int\/chp\/topics\/rheumatic\/en\/index.html"},{"key":"712_CR22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bone.2007.10.019","volume":"42","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, Adams J, Borgstr\u00f6m F, Cooper C, J\u00f6nsson B, Preedy D et al (2008) The cost-effectiveness of alendronate in the management of osteoporosis. Bone 42:4\u201315","journal-title":"Bone"},{"key":"712_CR23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta9220","volume":"9","author":"M Stevenson","year":"2005","unstructured":"Stevenson M, Lloyd Jones M, De Nigris E, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1\u2013160","journal-title":"Health Technol Assess"},{"key":"712_CR24","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B (2004) Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge. Value Health 7:518\u2013528","journal-title":"Value Health"},{"key":"712_CR25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s001980200106","volume":"13","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Jonsson B (2002) Economic evaluation of interventions for osteoporosis. Osteoporos Int 13:765\u2013767","journal-title":"Osteoporos Int"},{"key":"712_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11070","volume":"11","author":"JA Kanis","year":"2007","unstructured":"Kanis JA, Stevenson M, McCloskey EV, Davis S, Lloyd-Jones M (2007) Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 11:1\u2013256","journal-title":"Health Technol Assess"},{"key":"712_CR27","volume-title":"Guide to the methods of technology appraisal","author":"National Institute for Clinical Excellence","year":"2004","unstructured":"National Institute for Clinical Excellence (2004) Guide to the methods of technology appraisal. Abbo Litho Sales, London"},{"key":"712_CR28","volume-title":"Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women","author":"National Institute for Health and Clinical Excellence","year":"2007","unstructured":"National Institute for Health and Clinical Excellence (2007) Final appraisal determination. Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. NICE, London"},{"key":"712_CR29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta6290","volume":"6","author":"JA Kanis","year":"2002","unstructured":"Kanis JA, Brazier JE, Stevenson M, Calvert NW, Lloyd Jones M (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 6:1\u2013146","journal-title":"Health Technol Assess"},{"key":"712_CR30","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1007\/s00198-004-1643-0","volume":"15","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Borgstrom F, Johnell O, J\u00f6nsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int 15:862\u2013871","journal-title":"Osteoporos Int"},{"key":"712_CR31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, Johnell O, Oden A, Sykes D, J\u00f6nsson B (2005) Cost-effectiveness of raloxifene in the UK. An economic evaluation based on the MORE study. Osteoporosis Int 16:15\u201325","journal-title":"Osteoporosis Int"},{"key":"712_CR32","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00198-004-1623-4","volume":"16","author":"JA Kanis","year":"2004","unstructured":"Kanis JA, Johnell O, Oden A, Borgstrom F, Johansson H, De Laet C et al (2004) Intervention thresholds for osteoporosis in men and women. A study based on data from Sweden. Osteoporos Int 16:6\u201314","journal-title":"Osteoporos Int"},{"key":"712_CR33","volume-title":"Physician\u2019s guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation (NOF)","year":"2003","unstructured":"National Osteoporosis Foundation (NOF) (2003) Physician\u2019s guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DC"},{"key":"712_CR34","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00198-004-1811-2","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Johnell O, Committee of Scientific Advisors of the International Osteoporosis Foundation (2005) Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 16:229\u2013238","journal-title":"Osteoporos Int"},{"key":"712_CR35","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1359\/jbmr.2004.19.6.906","volume":"19","author":"H Johansson","year":"2004","unstructured":"Johansson H, Oden A, Johnell O, Jonsson B, De Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimisation of BMD measurements to identify high risk groups for treatment\u2014a test analysis. J Bone Miner Res 19:906\u2013913","journal-title":"J Bone Miner Res"},{"key":"712_CR36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00198-007-0550-6","volume":"19","author":"AN Tosteson","year":"2008","unstructured":"Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437\u2013447","journal-title":"Osteoporos Int"},{"key":"712_CR37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00198-008-0559-5","volume":"19","author":"B Dawson-Hughes","year":"2008","unstructured":"Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, Baim S, Favus MJ, Khosla S, Lindsay RL, National Osteoporosis Foundation Guide Committee (2008) Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 19:449\u2013458","journal-title":"Osteoporos Int"},{"issue":"Suppl 1","key":"712_CR38","first-page":"S65","volume":"19","author":"F Borgstr\u00f6m","year":"2008","unstructured":"Borgstr\u00f6m F, Str\u00f6m O, Kanis JA (2008) What proportion of patients can be treated with second line at a maintained incremental cost utility ratio. Osteoporos Int 19(Suppl 1):S65","journal-title":"Osteoporos Int"},{"key":"712_CR39","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"SR Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson D et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"712_CR40","volume-title":"Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis","author":"Food and Drug Administration","year":"1994","unstructured":"Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Rockville"},{"key":"712_CR41","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"KG Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339:292\u2013299","journal-title":"N Engl J Med"},{"key":"712_CR42","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"JD Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD et al (2001) Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u2013211","journal-title":"Arthritis Rheum"},{"key":"712_CR43","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"712_CR44","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"JE Roussow","year":"2002","unstructured":"Roussow JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial. JAMA 288:321\u2013333","journal-title":"JAMA"},{"key":"712_CR45","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A et al (2007) Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135\u2013141","journal-title":"J Bone Miner Res"},{"key":"712_CR46","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1136\/bmj.308.6936.1081","volume":"308","author":"MC Chapuy","year":"1994","unstructured":"Chapuy MC, Arlot ME, Delmas PD, Meunier PJ (1994) Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ 308:1081\u20131082","journal-title":"BMJ"},{"key":"712_CR47","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00198-004-1698-y","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Barton I, Johnell O (2005) Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 16:475\u2013482","journal-title":"Osteoporos Int"},{"key":"712_CR48","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","volume":"19","author":"EV McCloskey","year":"2004","unstructured":"McCloskey EV, Selby P, Davies M et al (2004) Clodronate reduces vertebral fracture risk in women with post-menopausal or secondary osteoporosis: results of a double blind placebo-controlled 3\u00a0year study. J Bone Miner Res 19:728\u2013736","journal-title":"J Bone Miner Res"},{"key":"712_CR49","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1359\/jbmr.060101","volume":"21","author":"C Roux","year":"2006","unstructured":"Roux C, Reginster JY, Fechtenbaum J et al (2006) Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 21:536\u2013542","journal-title":"J Bone Miner Res"},{"key":"712_CR50","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1359\/jbmr.2003.18.1.18","volume":"18","author":"R Marcus","year":"2003","unstructured":"Marcus R, Wang O, Satterwhite J et al (2003) The skeletal response to teriparatide is largely independent of age, initial bone mineral density and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 18:18\u201323","journal-title":"J Bone Miner Res"},{"key":"712_CR51","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","volume":"19","author":"O Johnell","year":"2004","unstructured":"Johnell O, Kanis JA, Black DM et al (2004) Association between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 19:764\u2013772","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"712_CR52","first-page":"S46","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Johansson H, Oden A, Aropuu S, Jalava T, Kanis JA (2007) Efficacy of clodronate on fracture risk in women selected by 10-year fracture probability. J Bone Miner Res 22(Suppl 1):S46","journal-title":"J Bone Miner Res"},{"key":"712_CR53","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333\u2013340","journal-title":"N Engl J Med"},{"key":"712_CR54","doi-asserted-by":"crossref","unstructured":"Johansson H, Kanis JA, Oden A, Johnell O, McCloskey EV (2008) BMD, clinical risk factors and their combination for hip fracture prevention. Unpublished","DOI":"10.1007\/s00198-009-0845-x"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0712-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-008-0712-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0712-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:00:58Z","timestamp":1558623658000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0712-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,28]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,10]]}},"alternative-id":["712"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0712-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,28]]}}}